GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis

Affiliations

Comment

Eberhard Standl. Lancet Diabetes Endocrinol. 2019 Oct.

. 2019 Oct;7(10):741-743.

doi: 10.1016/S2213-8587(19)30267-0. Epub 2019 Aug 14.

¹ Munich Diabetes Research Group eV at Helmholtz Center, Neuherberg 85764, Germany. Electronic address: eberhard.standl@lrz.uni-muenchen.de.

No abstract available

Comment on

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Kristensen SL, et al. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14. Lancet Diabetes Endocrinol. 2019. PMID: 31422062